Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


Purpose:

Randomized phase I trial to compare the effectiveness of two different vaccines given directly into the tumor in treating patients who have metastatic solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. It is not yet known which vaccine may be more effective in treating metastatic solid tumors


Study summary:

PRIMARY OBJECTIVES: I. To determine and compare the feasibility and clinical toxicity of administering rF-B7.1 and rF-TRICOM vaccines to patients with accessible cutaneous, subcutaneous, or lymph node metastatic tumors. II. To determine and compare the feasibility and clinical toxicity of administering rF-B7.1 and rF-TRICOM vaccines to patients with accessible visceral metastatic tumors. III. To determine the optimal dose of rF-B7.1 and rF-TRICOM vaccine delivered by intra-tumoral injection. IV. To compare the clinical responses and safety profile of patients with cutaneous tumors and visceral tumors who receive rF-B7.1 vaccine to similar patients receiving rF-TRICOM vaccine. SECONDARY OBJECTIVES: I. To establish evidence of host anti-tumor immune reactivity following intra-lesional vaccine administration and compare any differences between rF-B7.1 and rF-TRICOM in patients with cutaneous tumors and visceral tumors. II. To evaluate the quality of life during vaccine administration. OUTLINE: This is a randomized study with dose-escalation component. Patients are stratified according to tumor location (cutaneous, subcutaneous, or lymph node metastases vs visceral metastases). Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive rF-B7.1 vaccine intratumorally on day 1. ARM II: Patients receive fowlpox-TRICOM vaccine intratumorally on day 1. Treatment in both arms repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive additional courses. Three patients from the cutaneous disease (CD) stratum are treated at low-dose in each treatment arm. If no more than 1 of 6 patients experience dose-limiting toxicity (DLT), then 6 additional CD patients are randomized to high-dose treatment. If no more than 1 of these 6 patients experience DLT, then 12 patients from the visceral disease (VD) stratum are randomized to low-dose treatment. If no more than 2 of 12 VD patients experience DLT, then the next cohort of 12 VD patients is randomized to high-dose treatment. If 3 of the original 12 VD patients experience DLT, then 6 additional VD patients receive low-dose treatment. If no more than 3 of 18 patients experience DLT, then 12 VD patients receive high-dose treatment. Quality of life is assessed at baseline, monthly during therapy, and then at the end of therapy. Patients are followed every 3 months.


Criteria:

Inclusion Criteria: - Histologically confirmed metastatic unresectable solid tumors - Cutaneous, subcutaneous, lymph node, or visceral tumors that are accessible to imaging and injections - No standard therapy available - At least 1 unidimensionally measurable lesion - At least 20 mm for visceral lesions - At least 10 mm for cutaneous, subcutaneous, and nodal lesions - No untreated or edematous metastatic brain lesions - At least 6 weeks since prior surgery and/or radiotherapy for brain metastases and no evidence of disease or edema on CT scan or MRI - No ascites or pleural effusions - No leptomeningeal disease - Performance status - ECOG 0-1 - More than 3 months - Absolute granulocyte count at least 3,000/mm^3 - Platelet count at least 100,000/mm^3 - No bleeding diathesis - Bilirubin no greater than 1.5 mg/dL* - SGOT/SGPT no greater than 2 times upper limit of normal (ULN)* - Alkaline phosphatase no greater than 2 times ULN* - No elevated PT or PTT - No cirrhosis - No active hepatitis - No hepatic insufficiency - Creatinine no greater than 2.0 mg/dL - No renal insufficiency - No chronic obstructive pulmonary disorder - No active autoimmune disorders - No active immunologically mediated disease (e.g., severe psoriasis, colitis, idiopathic thrombocytopenic purpura, multiple sclerosis, connective tissue disease, or active rheumatoid arthritis) - No significant allergy or hypersensitivity to eggs - No active seizure disorder - No active or chronic infections - No other significant medical disease that would preclude study participation - No other malignancy within the past 5 years except stage I cervical cancer or basal cell carcinoma - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - More than 8 weeks since prior immunotherapy and recovered - More than 4 weeks since prior chemotherapy and recovered - At least 4 weeks since prior systemic corticosteroids - No concurrent corticosteroids - More than 2 weeks since prior radiotherapy and recovered - No evidence of bone marrow toxicity from prior radiotherapy - More than 4 weeks since prior surgery and recovered


Study is Available At:


Original ID:

NCI-2012-02455


NCT ID:

NCT00030693


Secondary ID:

CPMC-IRB-14535


Study Acronym:


Brief Title:

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors


Official Title:

Intra-Lesional rF-B7.1 Versus rF-Tricom Vaccine In The Treatment Of Metastatic Cancer


Overall Status:

Terminated


Study Phase:

Phase 1


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Cancer Institute (NCI)


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:

Administratively complete.


Study Type:

Interventional


Study Design:

Allocation: Randomized, Endpoint Classification:


Number of Arms:

2


Number of Groups:

0


Total Enrollment:

42


Enrollment Type:

Actual


Overall Contact Information

Official Name:Howard Kaufman
Principal Investigator
Mount Sinai School of Medicine

Study Dates

Start Date:December 2001
Primary Completion Date:April 2010
Primary Completion Type:Actual
Verification Date:January 2013
Last Changed Date:January 23, 2013
First Received Date:February 14, 2002

Study Outcomes

Outcome Type:Primary Outcome
Measure:Percentages of the DLTEs
Time Frame:12 weeks
Safety Issues:True
Description:Will be summarized and compared between arms, doses, and disease groups using Fisher's exact test.
Outcome Type:Secondary Outcome
Measure:Proportion of patients with any response (CR, PR, or SD)
Time Frame:12 weeks
Safety Issues:False
Description:First, the proportion with any response (CR, PR or SD) will be compared to those with no response (PD). Secondly, the proportion of any response (CR, PR or SD) compared to no response (PD) will be compared between the two treatment arms.
Outcome Type:Secondary Outcome
Measure:Immune response
Time Frame:12 weeks
Safety Issues:False
Description:Number of T-cells after treatment compared to those measured at baseline, and difference calculated as after-treatment minus baseline. First comparison includes all subjects who completed treatment. Mean change in T-Cells (final-baseline) tested against 0
Outcome Type:Secondary Outcome
Measure:Change in quality of life, assessed using the FACT-G survey of emotional and functional well being
Time Frame:Baseline to 12 weeks
Safety Issues:False
Description:A mean observed change in the FACT-G score will be tested against 0 (no change) for the group as a whole. Secondly, the change in score will be compared between the two treatment arms. The overall mean change will also be compared to historical controls e

Study Interventions

Intervention Type:Biological
Name:recombinant fowlpox-B7.1 vaccine
Description:Given intratumorally
Arm Name:Arm I (recombinant fowlpox-B7.1 vaccine)
Other Name:rF-B7.1
Intervention Type:Biological
Name:recombinant fowlpox-TRICOM vaccine
Description:Given intratumorally
Arm Name:Arm II (recombinant fowlpox-TRICOM vaccine)
Other Name:rF-TRICOM (B7.1.iCAM1-LFA3-Fowlpox)
Intervention Type:Other
Name:laboratory biomarker analysis
Description:Correlative studies
Arm Name:Arm I (recombinant fowlpox-B7.1 vaccine)
Intervention Type:Procedure
Name:quality-of-life assessment
Description:Ancillary studies
Arm Name:Arm I (recombinant fowlpox-B7.1 vaccine)
Other Name:quality of life assessment

Study Arms

Study Arm Type:Experimental
Arm Name:Arm I (recombinant fowlpox-B7.1 vaccine)
Description:Patients receive rF-B7.1 vaccine intratumorally on day 1.
Study Arm Type:Experimental
Arm Name:Arm II (recombinant fowlpox-TRICOM vaccine)
Description:Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.